NYSE:CC - Chemours Stock Price, Forecast & News

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours announced a quarterly dividend on Wednesday, February 12th. Shareholders of record on Thursday, February 27th will be given a dividend of $0.25 per share on Monday, March 16th. This represents a $1.00 annualized dividend and a yield of 5.14%. The ex-dividend date is Wednesday, February 26th. View Chemours' Dividend History.

Chemours Co (NYSE:CC) posted its earnings results on Thursday, February, 13th. The specialty chemicals company reported $0.56 EPS for the quarter, topping the Zacks' consensus estimate of $0.42 by $0.14. The specialty chemicals company earned $1.35 billion during the quarter, compared to the consensus estimate of $1.37 billion. Chemours had a negative net margin of 0.92% and a positive return on equity of 52.65%. View Chemours' Earnings History.

Chemours is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Chemours.

Chemours updated its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of $2.60-$3.55 for the period, compared to the Thomson Reuters consensus estimate of $3.22.

12 equities research analysts have issued 1-year price objectives for Chemours' shares. Their forecasts range from $14.50 to $42.00. On average, they expect Chemours' stock price to reach $23.15 in the next twelve months. This suggests a possible upside of 19.1% from the stock's current price. View Analyst Price Targets for Chemours.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 7 hold ratings, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chemours.

Headlines about CC stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chemours earned a daily sentiment score of 2.6 on InfoTrie's scale. They also assigned news stories about the specialty chemicals company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Chemours.

Chemours saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 14,520,000 shares, a decline of 11.3% from the January 15th total of 16,370,000 shares. Based on an average daily volume of 2,610,000 shares, the days-to-cover ratio is currently 5.6 days. Currently, 9.0% of the company's shares are sold short. View Chemours' Current Options Chain.

Some companies that are related to Chemours include ASAHI KASEI COR/ADR (AHKSY), Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Balchem (BCPC), Olin (OLN), Ingevity (NGVT), Innospec (IOSP), PQ Group (PQG), Livent (LTHM), GCP Applied Technologies (GCP) and Innophos (IPHS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Johnson & Johnson (JNJ), Pfizer (PFE) and Intel (INTC).

Chemours' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.54%), LSV Asset Management (2.53%), State Street Corp (2.42%), Bank of New York Mellon Corp (1.95%), Geode Capital Management LLC (1.10%) and Charles Schwab Investment Management Inc. (0.84%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View Institutional Ownership Trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Alberta Investment Management Corp, Connor Clark & Lunn Investment Management Ltd., W.E. Donoghue & Co. LLC, Envestnet Asset Management Inc., Robeco Institutional Asset Management B.V., NEXT Financial Group Inc and Acadian Asset Management LLC. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Mark Newman, Mark P Vergnano and Paul Kirsch. View Insider Buying and Selling for Chemours.

CC stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Great Lakes Advisors LLC, Bank of New York Mellon Corp, First Trust Advisors LP, Anavon Capital LLP, Blackcrane Capital LLC, DT Investment Partners LLC and UBS Asset Management Americas Inc.. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown and Susan M Kelliher. View Insider Buying and Selling for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CC stock can currently be purchased for approximately $19.44.

Chemours has a market capitalization of $3.19 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. Chemours employs 7,000 workers across the globe.View Additional Information About Chemours.

The official website for Chemours is http://www.chemours.com/.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]